Using syndicated survey data from YouGov Profiles and BrandIndex in tandem with deep-dive custom research, YouGov's InternationalFMCG/CPGReport for 2021 investigates how attitudes and behaviors have shifted within each market.
DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that Valneva SE reported positive initial results for Part A of the Phase 1/2 clinical trial of Valneva's inactivated COVID-19 vaccine candidate, VLA2001, using Dynavax's CpG 1018™ adjuvant in 153 healthy adults aged 18 to 55 years.
PositivePhase 1/2 Results for Valneva's Inactivated COVID-19 Vaccine Candidate Using Dynavax's CpG 1018™ Adjuvant. April 6, 2021 VLA2001, an inactivated COVID-19 vaccine candidate with CpG 1018 adjuvant, was highly immunogenic and generally ... and CpG 1018 ... About CpG 1018 Adjuvant.